2-[3-chloro-6-[2,2-difluoro-2-(1-oxidopyridin-1-ium-2-yl)ethyl]imino-1-hydroxypyridin-2-yl]-N-[(1R)-1-(3-chlorophenyl)ethyl]acetamide

2-[3-chloro-6-[2,2-difluoro-2-(1-oxidopyridin-1-ium-2-yl)ethyl]imino-1-hydroxypyridin-2-yl]-N-[(1R)-1-(3-chlorophenyl)ethyl]acetamide is an experimental small molecule direct thrombin inhibitor (DTI) developed by Merck & Co. It belongs to a series of pyridinone-based anticoagulants designed to bind reversibly to the active site of thrombin (Factor IIa). By inhibiting thrombin, the compound prevents the conversion of fibrinogen into fibrin, thereby blocking the final step of the coagulation cascade. This molecule was primarily investigated as a research tool or preclinical candidate for the treatment and prevention of thrombotic disorders, such as deep vein thrombosis and pulmonary embolism, though it did not progress to clinical approval.

Other names

DB04722DB-04722DB 04722pyridinone thrombin inhibitor